Improving Digit-Symbol Scores Across Cannabis Conditions Were Consistent With Practice

When digit-symbol scores improved in every treatment condition, improvement alone did not demonstrate a beneficial cannabis effect. The review identified practice as a plausible explanation for that shared trajectory.

The comparison included placebo

In a spinal-cord-related neuropathic-pain trial, repeated Digit Symbol Test scores improved over time across conditions. The review reports no significant dose-effect differences on that measure and describes the common improvement as consistent with practice effects.

Within-condition gains are not a treatment advantage

A participant can become more familiar with a task during repeated testing. If the control condition improves as well, a higher later score is not independently evidence of pharmacological cognitive enhancement. The relevant treatment inference needs a comparison accounting for that shared change.

Practice was an interpretation rather than a uniquely proven cause

The pattern supports the explanation but does not isolate every contributor, such as changing symptoms or other session effects. It also does not invalidate different tasks that did show THC-related differences in the same trial. The balanced account preserves a task-specific null drug comparison and the improvement common to conditions. Such information helps prevent a repeated-testing gain from being advertised as a cannabis benefit or used to erase a separate observed deficit.

Related analysis: the review’s broader findings and limitations.

Research cited

This analysis draws on the supplied review: Eadie and colleagues (2021). Duration of Neurocognitive Impairment With Medical Cannabis Use: A Scoping Review. Frontiers in Psychiatry.

Study discussed in that review: DOI 10.1016/j.jpain.2016.05.010.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

Late Sheep Fat Biopsies Supplied Residue Evidence Beyond the Plasma THC Curve

The sheep study measured THC in subcutaneous fat as well as plasma. Positive biopsies at selected later dates and subsequent nondetections did not identify an exact clearance day for every animal. The tissue sampling schedule differed between animals The pilot animal had fat sampled at fourteen, twenty-eight and fifty-six days….

Spread the love

Read Article: Late Sheep Fat Biopsies Supplied Residue Evidence Beyond the Plasma THC Curve

Sheep THC Clearance and Distribution Estimates Depended on a Small Bioavailability Pilot

The sheep paper’s clearance and distribution estimates relied on an approximate oral-bioavailability value from a two-animal pilot. The numerical estimates should retain that assumption rather than being treated as independently established species constants. The pilot supplied a limited reference One sheep received intravenous THC and another oral THC. The paper…

Spread the love

Read Article: Sheep THC Clearance and Distribution Estimates Depended on a Small Bioavailability Pilot

Split Dosing Qualified the Very Late THC Peak Reported in Sheep

The sheep pharmacokinetic study’s late plasma THC peak followed a dose split into two administrations twelve hours apart. That timing should not be presented as the absorption profile of one ordinary meal or a single human dose. The clock began with the first half of the dose The discussion reports…

Spread the love

Read Article: Split Dosing Qualified the Very Late THC Peak Reported in Sheep

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us